4D Pharma results disappoint markets

By
0 mins. to read
4D Pharma results disappoint markets

Shares in AIM-listed drug firm 4D Pharma (LON:DDDD) dropped by 13.68% to 45.75p (as of 16:20 BST) after it reported a post-tax loss of £23.7 million for the year ended 31st December. Net assets dropped by more than 50% as the company ran clinical trials across a number of product lines.

Chairman Axel Glasmacher commented: “I am pleased to be able to announce the Group’s final results for the year ended 31 December 2019. 2019 was a successful year for the Group in which we made great progress in the clinic across multiple programmes, and entered collaborations with new partners. I would like to thank everyone in the Group for their valuable contributions as we look ahead to a pivotal year for 4D as we reach key readouts from multiple clinical studies“.

On 30th July at 1pm we’ll be holding the next live Q&A webinar with the Master Investor himself, Jim Mellon. Please share a question for Jim below and we’ll try to answer as many as possible in the live webinar. Sign up for the webinar here.

Are you interested in joining Jim's webinar?


Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *